BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21780742)

  • 1. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
    Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
    J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
    Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
    ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
    Tran AT; West NP; Britton WJ; Payne RJ
    ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach.
    Schmidt MF; Korb O; Howard NI; Dias MV; Blundell TL; Abell C
    ChemMedChem; 2013 Jan; 8(1):54-8. PubMed ID: 23169689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of potent ene-yne inhibitors of type II dehydroquinases as tuberculosis drug leads.
    Tran AT; Cergol KM; West NP; Randall EJ; Britton WJ; Bokhari SA; Ibrahim M; Lapthorn AJ; Payne RJ
    ChemMedChem; 2011 Feb; 6(2):262-5. PubMed ID: 21275049
    [No Abstract]   [Full Text] [Related]  

  • 6. A new family of inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
    Gasse C; Huteau V; Douguet D; Munier-Lehmann H; Pochet S
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1057-61. PubMed ID: 18058536
    [No Abstract]   [Full Text] [Related]  

  • 7. Determination of the bound conformation of a competitive nanomolar inhibitor of mycobacterium tuberculosis type II dehydroquinase by NMR spectroscopy.
    Prazeres VF; Sánchez-Sixto C; Castedo L; Canales A; Cañada FJ; Jiménez-Barbero J; Lamb H; Hawkins AR; González-Bello C
    ChemMedChem; 2006 Sep; 1(9):990-6. PubMed ID: 16952136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues.
    Prazeres VF; Tizón L; Otero JM; Guardado-Calvo P; Llamas-Saiz AL; van Raaij MJ; Castedo L; Lamb H; Hawkins AR; González-Bello C
    J Med Chem; 2010 Jan; 53(1):191-200. PubMed ID: 19911771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.
    Mao J; Yuan H; Wang Y; Wan B; Pak D; He R; Franzblau SG
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1263-8. PubMed ID: 20022500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and structural analysis of aromatic inhibitors of type II dehydroquinase from Mycobacterium tuberculosis.
    Howard NI; Dias MV; Peyrot F; Chen L; Schmidt MF; Blundell TL; Abell C
    ChemMedChem; 2015 Jan; 10(1):116-33. PubMed ID: 25234229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of new bifunctional inhibitors of type II dehydroquinase.
    Toscano MD; Stewart KA; Coggins JR; Lapthorn AJ; Abell C
    Org Biomol Chem; 2005 Sep; 3(17):3102-4. PubMed ID: 16106291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design, synthesis, and biological evaluation of inhibitors of Mycobacterium tuberculosis type II dehydroquinase.
    Sánchez-Sixto C; Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
    J Med Chem; 2005 Jul; 48(15):4871-81. PubMed ID: 16033267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism.
    Toscano MD; Payne RJ; Chiba A; Kerbarh O; Abell C
    ChemMedChem; 2007 Jan; 2(1):101-12. PubMed ID: 17068841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
    Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
    ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the key factors that control the inhibition of type II dehydroquinase by (2R)-2-benzyl-3-dehydroquinic acids.
    Peón A; Otero JM; Tizón L; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Gago F; Castedo L; González-Bello C
    ChemMedChem; 2010 Oct; 5(10):1726-33. PubMed ID: 20815012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
    Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
    Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: an attempt to improve the activity against Mycobacterium tuberculosis.
    Andaloussi M; Lindh M; Björkelid C; Suresh S; Wieckowska A; Iyer H; Karlén A; Larhed M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5403-7. PubMed ID: 21824775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs.
    Sriram D; Yogeeswari P; Gopal G
    Eur J Med Chem; 2005 Dec; 40(12):1373-6. PubMed ID: 16129516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis.
    Banerjee DR; Biswas R; Das AK; Basak A
    Eur J Med Chem; 2015 Jul; 100():223-34. PubMed ID: 26092447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity.
    Eng WS; Hocková D; Špaček P; Janeba Z; West NP; Woods K; Naesens LM; Keough DT; Guddat LW
    J Med Chem; 2015 Jun; 58(11):4822-38. PubMed ID: 25915781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.